18F-FET PET/CT in the Management of Glioma
Prospective Investigation in the Utility of Multiparametric 18F-FET PET/CT in the Management of Glioma: Application of PET Radiomics
1 other identifier
interventional
36
1 country
1
Brief Summary
O-(2-\[18F\]-fluoroethyl)-L-tyrosine (FET) is a tracer for positron emission tomography (PET). The Response Assessment in Neuro-Oncology (RANO) working group has officially recommended 18F-FET PET in the management of patients with brain glioma. Recently, the utility of 18F-FET PET in the diagnosis of fresh and residual gliomas has been reported by several investigators. But clinical usefulness of radiomics parameters has not been explored thoroughly in glioma patients. 18F-FET PET has been widely used in clinical studies or routine service in Europe, America, Mainland China, or Japan. However, 18F-FET PET is still not available in Taiwan. In this context, the investigator propose this study to explore the role of multiparametric 18F-FET PET imaging for glioma in Taiwan, with the emphasis in radiomics analysis.
Trial Health
Trial Health Score
Automated assessment based on enrollment pace, timeline, and geographic reach
participants targeted
Target at P25-P50 for not_applicable
Started Aug 2020
Longer than P75 for not_applicable
1 active site
Health score is calculated from publicly available data and should be used for screening purposes only.
Trial Relationships
Click on a node to explore related trials.
Study Timeline
Key milestones and dates
Study Start
First participant enrolled
August 1, 2020
CompletedPrimary Completion
Last participant's last visit for primary outcome
December 30, 2023
CompletedStudy Completion
Last participant's last visit for all outcomes
December 30, 2023
CompletedFirst Submitted
Initial submission to the registry
August 18, 2024
CompletedFirst Posted
Study publicly available on registry
August 20, 2024
CompletedAugust 20, 2024
August 1, 2024
3.4 years
August 18, 2024
August 18, 2024
Conditions
Keywords
Outcome Measures
Primary Outcomes (1)
Overall survival
Overall survival is measured from the date of diagnosis to the date of death, or censored at last follow-up date.
3 years
Study Arms (1)
18F-FET PET
EXPERIMENTALThe study participants receive the 18F-FET PET scan.
Interventions
Eligibility Criteria
You may qualify if:
- Patients with primary or recurrent brain tumors confirmed by pathological examination or imaging studies.
- The ability to provide written informed consent and receive the scheduled scan.
You may not qualify if:
- Woman with pregnancy or during lactation.
- Unsuitable for PET scans, such as those with claustrophobia or inability to lie flat.
- Unable to sign the informed consent form.
- Patients with a second primary tumor.
Contact the study team to confirm eligibility.
Sponsors & Collaborators
Study Sites (1)
Hualien Tzu Chi Hospital
Hualien City, Taiwan
Related Publications (1)
Chan SC, Chiu TL, Ng SH, Kao HW, Tsai ST, Liu SH. 18F-FET PET/CT can aid in diagnosing patients with indeterminate MRI findings for brain tumors: a prospective study. Ann Nucl Med. 2025 Apr;39(4):342-352. doi: 10.1007/s12149-024-02005-4. Epub 2024 Nov 26.
PMID: 39589672DERIVED
MeSH Terms
Conditions
Condition Hierarchy (Ancestors)
Study Officials
- STUDY DIRECTOR
Sheng-Chieh Chan
Hualien Tzu Chi General Hospital
Study Design
- Study Type
- interventional
- Phase
- not applicable
- Allocation
- NA
- Masking
- NONE
- Purpose
- DIAGNOSTIC
- Intervention Model
- SINGLE GROUP
- Sponsor Type
- OTHER
- Responsible Party
- SPONSOR
Study Record Dates
First Submitted
August 18, 2024
First Posted
August 20, 2024
Study Start
August 1, 2020
Primary Completion
December 30, 2023
Study Completion
December 30, 2023
Last Updated
August 20, 2024
Record last verified: 2024-08
Data Sharing
- IPD Sharing
- Will not share